The Roche Q3 2026 results give industry readers a read on how a large pharmaceutical company is preparing for patent expiries: sales of CHF 16.13 billion, up 7% at constant exchange rates, were ahead of expectations on 22 October 2026, while the pipeline and a stream of external licensing deals, many with Chinese partners, carry the company’s growth plans.
Key takeaways from the Roche Q3 2026 results for the pharma industry
- Group sales were CHF 16.13 billion, up 7% at constant exchange rates, against company-compiled consensus of CHF 15.75 billion.
- Diagnostics grew 5% to CHF 3.54 billion; Ocrevus rose 9% at constant currencies to CHF 1.84 billion.
- Xolair came in at CHF 848 million, below expectations of about CHF 925 million, after a lower-priced rival launched.
- Roche reaffirmed mid-single-digit group sales growth for 2026.
- A reported licensing deal with Hansoh Pharma is worth more than USD 15 billion in total, with CHF 400 million upfront.
Dealmaking in the Roche Q3 2026 results
Roche’s strategy is shaped by the fact that several older blockbusters are nearing patent expiry. The company is expanding external dealmaking for next-generation treatments. A report says the Hansoh Pharma agreement, reported earlier in the week, is worth more than USD 15 billion including milestones and royalties, with CHF 400 million upfront and CHF 110 million after one year. The same report notes that Chinese companies have licensed 11 deals to Roche since the start of 2025 and six in the last two months, according to trade-press data.
Chief executive Thomas Schinecker said about half of Roche’s licensing deals over four years were made in the US and half in China and Asia, adding that this shows where Europe stands on innovation. The company’s investor information is on roche.com.
Pipeline events after the Roche Q3 2026 results
- Giredestrant, a breast cancer pill: FDA decision expected by 18 December; executives say it could become a best seller but it would enter a crowded field.
- Fenebrutinib, an experimental multiple sclerosis therapy: awaiting an FDA answer, with questions surrounding it, according to a trade-press report.
- Obesity programmes: Roche has said obesity drugs and giredestrant could together reach about USD 9 billion in peak annual sales, though the obesity market is dominated by Eli Lilly and Novo Nordisk.
These are statements and assessments reported by the press and attributed to executives or analysts. They are not guarantees of regulatory outcomes.
The Xolair signal in the Roche Q3 2026 results
Xolair sales were CHF 848 million against expectations of about CHF 925 million, which by our own arithmetic is a gap of roughly CHF 77 million, or 8%. Reports link the shortfall to the first cheaper copy launching in the US this month. They do not name the competing product in a way we can confirm, and we do not.
Acumen Research and Consulting’s report Biosimilars Market Size, Share, Analysis, Trends and Forecast 2024 to 2032 estimates the global biosimilars market at USD 26.7 billion in 2023, rising to USD 113.2 billion by 2032 at a CAGR of 17.5%. It also states that North America was the largest region at around USD 10.7 billion in 2023, and that monoclonal antibodies are expected to dominate. These are market-wide estimates and not a forecast for any one drug. Regulators explain how such products are approved on the FDA biosimilars page.
Market access and the Roche Q3 2026 results
The market-access angle is how quickly payers move patients to lower-priced alternatives. A trade-press analysis says that once insurers and pharmacy benefit managers update coverage, patients can be switched quickly and brand owners may need to cut net prices. That is the author’s view. We have no data from Roche or from payers on how coverage has changed for Xolair.
Regional and divisional detail in the Roche Q3 2026 results
North America accounts for nearly half of Roche’s group revenue, according to a wire-service report, and a stronger dollar against the Swiss franc eased the currency drag there. China recorded double-digit declines, though the drag from its pricing reforms is easing. Diagnostics rose 5% to CHF 3.54 billion. Roche’s announcement headline also gives growth of 8% in Swiss francs for the quarter and 6% at constant rates for the first nine months. Shares fell 1.1% in morning trade, which is a market reaction and not a verdict on the quarter.
General background: reading a pharmaceutical earnings report
Analysts look at growth at constant exchange rates, product-level sales against consensus, guidance, pipeline milestones and one-off effects. A headline beat can hide weaker underlying performance, as one Jefferies analyst suggested here when he called the quarter cosmetically ahead and linked part of the revenue to a new resource planning system. See our pharmaceuticals coverage for related reports.
Our analysis: what the Roche Q3 2026 results mean for the industry
In our assessment, the Roche Q3 2026 results fit a pattern across large pharmaceutical companies: strong sales from current products, rising reliance on external innovation and growing exposure to lower-priced competition. China’s role as a source of licensed assets stands out in the reported deal counts.
We make no forecast for Roche’s share price or for the outcome of pending FDA decisions. Nothing here is investment advice.
What is not disclosed in the Roche Q3 2026 results coverage
- Pharmaceuticals division sales, not given in the reports we read.
- The competing Xolair product and its pricing.
- How much revenue came from the planning system change.
- Deal terms for Hansoh beyond the reported headline numbers.
Risks and caveats
This article relies on reports of the company announcement and on analyst opinion. Consensus numbers differ slightly between reports. Acumen’s figures are third-party estimates. This is news reporting and not investment advice.
What to watch next
- The FDA decisions on giredestrant and fenebrutinib.
- Further licensing deals with Chinese companies.
- Xolair sales as the competitor expands.
- Roche’s 2027 outlook.
FAQ
What did the Roche Q3 2026 results show?
Group sales of CHF 16.13 billion, up 7% at constant exchange rates, ahead of consensus.
What deals is Roche doing?
A reported licence from Hansoh Pharma worth more than USD 15 billion in total, with CHF 400 million upfront.
What does Acumen forecast for biosimilars?
USD 113.2 billion by 2032, from USD 26.7 billion in 2023, a CAGR of 17.5%.
How we reported this: we relied on the company announcement, wire and trade-press reports, and the Acumen Research and Consulting report cited above, and attributed every figure. Last updated 23 October 2026. This is news reporting and not advice.
